As mentioned earlier, Weickhardt et al. was one of the first to suggest that continuing targeted therapies beyond progression, combined with LAT, could benefit patients with oncogene-driver mutated NSCLC [5]. This evidence concerns the gene LAT and non-small cell lung carcinoma.